Role of the specific inhibitor of 5-lipoxygenase-activating protein MK886 in inhibiting alcoholic liver disease in mice

Yang ShuJuan; Guo YaLing; Fu Shan; He YingLi; Zhao YingRen; Tian Zhen

doi:10.3969/j.issn.1001-5256.2019.08.028

Volume 35 Issue 8

Aug. 2019

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2019 > 35(8): 1791-1796

PDF( 2715 KB)

Role of the specific inhibitor of 5-lipoxygenase-activating protein MK886 in inhibiting alcoholic liver disease in mice

DOI: 10.3969/j.issn.1001-5256.2019.08.028

Department of Infectious Diseases, The First Affiliated Hospital of Xi'an Jiaotong University

Research funding:

Received Date: 2019-03-19
Published Date: 2019-08-20

Abstract

Abstract

Objective To investigate the effect of MK886, a specific inhibitor of 5-lipoxygenase-activating protein (FLAP) , on alcoholic liver disease (ALD) in mice. Methods A total of 48 male Kunming mice were randomly divided into ALD group, ALD/MK886 group, control group, and normal group. The mice in the ALD group and the ALD/MK886 group were fed with Tipoe-Nanji alcohol liquid diet and were given alcohol by gavage 6 weeks later to establish a model of acute ALD. The mice in the control group were given control diet without alcohol, and those in the normal group were given normal diet. After 2 days of alcohol intake, the mice in the ALD/MK886 group were given intraperitoneally injected MK886 (0. 01 mg/10 g) once a day. The mice were sacrificed at 9 hours after the administration of alcohol by gavage. Serum levels of aspartate aminotransferase (AST) , alanine aminotransferase (ALT) , lactate dehydrogenase (LDH) , and triglyceride (TG) and the levels of TG and malondialdehyde (MDA) in liver tissue were measured. HE staining was performed for liver tissue and pathological score was determined. Western blot was used to measure the expression of FLAP and 5-lipoxygenase (5-LO) in liver tissue and Thp-1 cells, and flow cytometry was used to measure the apoptosis of Thp-1 cells. One-way ANOVA was used for comparison between groups; the least significant difference t-test was used for comparison of data with homogeneity of variance, and the Tamhane's T2 test was used for comparison of data with heterogeneity of variance. Results The ALD group and the ALD/MK886 group had a reduction in body weight within the first week of modeling, followed by a gradual increase; at the end of modeling, the ALD group had significantly lower bodyweight and liver index than the normal group and the control group (all P < 0. 05) , and the ALD/MK886 group had significantly higher body weight and liver index than the ALD group (both P < 0. 05) . Compared with the normal group and the control group, the ALD group had significant increases in the levels of AST, ALT, LDH, and TG in serum and the levels of TG and MDA in liver tissue (all P < 0. 05) , and compared with the ALD group, the ALD/MK886 group had significant reductions in the above indices (all P < 0. 05) . The ALD group had a significantly higher score of hepatic steatosis than the normal group and the control group (both P < 0. 05) , and compared with the ALD group, the ALD/MK886 group had a significant reduction in this score (P < 0. 05) . Compared with the normal group and the control group, the ALD group had significant increases in the expression of 5-LO and FLAP in the liver (all P < 0. 05) , and the ALD/MK886 group had significant reductions compared with the ALD group (P < 0. 05) . Lipopolysaccharide (LPS) upregulated the expression of FLAP and 5-LO in Thp-1 cells, and MK886 alleviated such effect of LPS (all P < 0. 05) ; MK886 promoted the apoptosis of Thp-1 cells, and LPS alleviated the effect of MK886 in promoting cell apoptosis (all P < 0. 01) . Conclusion MK886 can inhibit the expression of 5-LO, induce the apoptosis of Kupffer cells, and thus exert a therapeutic effect on ALD in mice.
- liver diseases, alcoholic,
- lipoxygenase,
- kupffer cell,
- apoptosis,
- mice, inbred C57BL

FullText(HTML)

References(21)

References

[1] OSNA NA, DONOHUE TM Jr, KHARBANDA KK. Alcoholic liver disease:Pathogenesis and current management[J]. Alcohol Res, 2017, 38 (2) :147-161.

[2] VASSALLO GA, TARLI C, RANDO MM, et a. Liver transplantation in patients with alcoholic liver disease:A retrospective study[J]. Alcohol Alcohol, 2018, 53 (2) :151-156.

[3] National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association;Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for alcoholic liver disease:A 2018 update[J]. J Clin Hepatol, 2018, 34 (5) :939-946. (in Chinese) 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会.酒精性肝病防治指南 (2018年更新版) [J].临床肝胆病杂志, 2018, 34 (5) :939-946.

[4] STICKEL F, DATZ C, HAMPE J, et al. Pathophysiology and management of alcoholic liver disease:Update 2016[J]. Gut Liver, 2017, 11 (2) :173-188.

[5] KOLIOS G, VALATAS V, KOUROUMALIS E. Role of Kupffer cells in the pathogenesis of liver disease[J]. World J Gastroenterol, 2006, 12 (46) :7413-7420.

[6] BALA S, CSAK T, KODYS K, et al. Alcohol-induced miR-155 and HDAC11 inhibit negative regulators of the TLR4 pathway and lead to increased LPS responsiveness of Kupffer cells in alcoholic liver disease[J]. J Leukoc Biol, 2017, 102 (2) :487-498.

[7] PARK JK, SHAO M, KIM MY, et al. An endoplasmic reticulum protein, Nogo-B, facilitates alcoholic liver disease through regulation of kupffer cell polarization[J]. Hepatology, 2017, 65 (5) :1720-1734.

[8] SORGI CA, ZARINI S, MARTIN SA, et al. Dormant 5-lipoxygenase in inflammatory macrophages is triggered by exogenous arachidonic acid[J]. Sci Rep, 2017, 7 (1) :10981.

[9] BRUNO F, ERRICO S, PACE S, et al. Structural insight into the optimization of ethyl 5-hydroxybenzo[g]indol-3-carboxylates and their bioisosteric analogues as 5-LO/m-PGES-1 dual inhibitors able to suppress inflammation[J]. Eur J Med Chem, 2018, 155:946-960.

[10] TITOS E, CLRIA J, PLANAGUMA, et al. Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury:Role of Kupffer cells[J]. J Leukoc Biol, 2005, 78 (4) :871-878.

[11] LEO LM, ALMEIDA-CORRA S, CANETTI CA, et al. Agedependent relevance of endogenous 5-lipoxygenase derivatives in anxiety-like behavior in mice[J]. PLo S One, 2014, 9 (1) :e85009.

[12] SUMMA KC, VOIGT RM, FORSYTH CB, et al. Disruption of the circadian clock in mice increases intestinal permeability and promotes alcohol-induced hepatic pathology and inflammation[J]. PLo S One, 2013, 8 (6) :e67102.

[13] DESMET VJ, KNODELL RG, ISHAK KG, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis[Hepatology 1981; 1:431-435][J]. J Hepatol, 2003, 38 (4) :382-386.

[14] MASARONE M, ROSATO V, DALLIO M, et al. Epidemiology and natural history of alcoholic liver disease[J]. Rev Recent Clin Trials, 2016, 11 (3) :167-174.

[15] LOUVET A, MATHURIN P. Alcoholic liver disease:Mechanisms of injury and targeted treatment[J]. Nat Rev Gastroenterol Hepatol, 2015, 12 (4) :231-242.

[16] SZABO G, PETRASEK J. Gut-liver axis and sterile signals in the development of alcoholic liver disease[J]. Alcohol Alcohol, 2017, 52 (4) :414-424.

[17] LIN XX, CHEN D, ZHAO Q, et al. Genetic reasearch on the incidence of alcoholic liver disease[J]. Chin J Clin Pharmacol Ther, 2017, 22 (11) :1309-1314. (in Chinese) 林秀贤, 陈丹, 赵青, 等.影响酒精性肝病发病的遗传学研究进展[J].中国临床药理学与治疗学, 2017, 22 (11) :1309-1314.

[18] NADARAJAN K, BALARAM P, KHOO BY. MK886 inhibits the pioglitazone-induced anti-invasion of MDA-MB-231 cells is associated with PPARα/γ, FGF4 and 5LOX[J]. Cytotechnology, 2016, 68 (5) :1771-1787.

[19] DAGLAR GO, KAMA NA, ATLI M, et al. Effect of 5-lipoxygenase inhibition on Kupffer cell clearance capacity in obstructive jaundiced rats[J]. J Surg Res, 2001, 96 (2) :158-162.

[20] ZHOU H, YU M, ZHAO J, et al. IRAKM-Mincle axis links cell death to inflammation:Pathophysiological implications for chronic alcoholic liver disease[J]. Hepatology, 2016, 64 (6) :1978-1993.

[21] KOOP DR, KLOPFENSTEIN B, IIMURO Y, et al. Gadolinium chloride blocks alcohol-dependent liver toxicity in rats treated chronically with intragastric alcohol despite the induction of CYP2E1[J]. Mol Pharmacol, 1997, 51 (6) :944-950.

Relative Articles

[1]	Ru JIA, Pingping ZHANG, Yuan YUAN, Yiyang HU, Qin FENG. Differences and application value of plasma bile acids in tumors of the liver[J]. Journal of Clinical Hepatology, 2024, 40(10): 2042-2048. doi: 10.12449/JCH241018
[2]	ZHANG ZhongLin, YUAN YuFeng. Key operating points of laparoscopic hepatectomy for liver tumor in difficult locations[J]. Journal of Clinical Hepatology, 2020, 36(12): 2663-2666. doi: 10.3969/j.issn.1001-5256.2020.12.006
[3]	Li ShanShan, Zhang Ke, Cheng ShuJie, Yang JiHong, Gao Feng, Li JingHua. Current status and future perspectives of the application of medical 3D visualization technology in accurate surgery of liver tumors[J]. Journal of Clinical Hepatology, 2019, 35(5): 1114-1117. doi: 10.3969/j.issn.1001-5256.2019.05.042
[4]	Wang ZhiYu, Gu SanWei, Chen XiaoQian, Cai YanJun. Clonorchiasis misdiagnosed as hepatic tumor: a case report[J]. Journal of Clinical Hepatology, 2018, 34(3): 602-603. doi: 10.3969/j.issn.1001-5256.2018.03.033
[5]	Qi Fei, Tang YingMei. The mechanism of chenodeoxycholic acid and its derivatives in hepatobiliary tumor[J]. Journal of Clinical Hepatology, 2018, 34(5): 1115-1118. doi: 10.3969/j.issn.1001-5256.2018.05.041
[6]	Chen HaiOu, Liu Shi, Lin YiHe. Expression of M30 and CCL20 in serum in patients with HBV-related acute-on-chronic liver failure and their clinical significance[J]. Journal of Clinical Hepatology, 2018, 34(4): 806-809. doi: 10.3969/j.issn.1001-5256.2018.04.022
[7]	Lu NingNing, Sun Bin, Cui XiongWei, Long Jiang, Gao WenFeng, Zheng JiaSheng. Diagnosis and treatment of subcapsular hemorrhage after liver tumor ablation[J]. Journal of Clinical Hepatology, 2017, 33(12): 2326-2330. doi: 10.3969/j.issn.1001-5256.2017.12.014
[8]	Zhao Zhao, Qi WenQian, Zhao Ping. Research advances in insulin-like growth factor 1 receptor and its pathway in diagnosis and treatment of primary liver cancer[J]. Journal of Clinical Hepatology, 2017, 33(4): 763-768. doi: 10.3969/j.issn.1001-5256.2017.04.038
[9]	Kong Li, Jin Meng, Zhao SuXian. Role of tumor necrosis factor- alpha- induced protein 8-like 2 in development and progression of liver and gastrointestinal tumors[J]. Journal of Clinical Hepatology, 2017, 33(1): 175-179. doi: 10.3969/j.issn.1001-5256.2017.01.041
[10]	Chen Wei, Zhou Yun, Gong JianPing. Role of tumor-associated macrophages in development and progression of primary liver cancer[J]. Journal of Clinical Hepatology, 2016, 32(7): 1422-1424. doi: 10.3969/j.issn.1001-5256.2016.07.048
[11]	Wang JinWei, Zhang YaMin. Research advances in methods for determination of tumor boundary in hepatectomy[J]. Journal of Clinical Hepatology, 2016, 32(2): 374-377. doi: 10.3969/j.issn.1001-5256.2016.02.039
[12]	Lin Kun, Ci DanWangJiu, Chang ZhiHui, Liu ZhaoYu. Clinical value of circulating micro RNAs in hepatic,biliary and pancreatic carcinomas[J]. Journal of Clinical Hepatology, 2015, 31(5): 790-795. doi: 10.3969/j.issn.1001-5256.2015.05.040
[13]	Chen XuXiao, Chen YongJun. PI3K / Akt / mTOR signaling pathway and malignant hepatobiliary tumors[J]. Journal of Clinical Hepatology, 2015, 31(6): 989-991. doi: 10.3969/j.issn.1001-5256.2015.06.040
[14]	Wang WuChen, Zhou YongNing. Research progress in tumor- associated antigen antibodies for diagnosis of liver cancer[J]. Journal of Clinical Hepatology, 2014, 30(6): 573-576. doi: 10.3969/j.issn.1001-5256.2014.06.025
[15]	Fang ZiYan, Huang Long, Li Gong. Research progress in radiotherapy for liver tumors reported in 2013 ASTRO Annual Meeting[J]. Journal of Clinical Hepatology, 2014, 30(4): 383-385. doi: 10.3969/j.issn.1001-5256.2014.04.025
[16]	Ji Bo, Liu YaHui. Research advances in role of myeloid- derived suppressor cells in tumorigenesis[J]. Journal of Clinical Hepatology, 2014, 30(9): 939-943. doi: 10.3969/j.issn.1001-5256.2014.09.026
[17]	Chen MinHua. Standardization of thermal ablation in treatment of liver tumor[J]. Journal of Clinical Hepatology, 2013, 29(8): 561-563. doi: 10.3969/j.issn.1001-5256.2013.08.001
[19]	Yang BiWei, Gan YuHong, Ye ShengLong, Zhang BoHeng, Ren ZhengGang, Xia JingLin, Wang YanHong, Ge NingLing, Chen Yi, Li LiXin, Le Fan, Zhang Lan. Necrosis range and safety of radiofrequency combined with systemic chemotherapy and radiofrequency alone.[J]. Journal of Clinical Hepatology, 2004, 20(6): 364-365.

Supplements(0)

Cited By

Cited by

Periodical cited type(30)

1.	汪淑佳，俞黎. 多学科团队诊疗模式下的PDCA循环管理在梗阻性黄疸患者围术期护理中的应用效果分析. 中国社区医师. 2025(02): 96-98 .
2.	易衡，何芬，王曦，冯谦，唐杰，卿小琼，孙菲菲，陈重. 超声引导下PTCD治疗晚期MOJ疗效及预后因素分析. 武汉大学学报(医学版). 2024(07): 814-819 .
3.	李鸿. 老年晚期恶性梗阻性黄疸患者实时超声弹性成像定量分析对PTCD预后的预测价值. 昆明医科大学学报. 2023(01): 122-127 .
4.	李鸿. 老年晚期恶性梗阻性黄疸患者实时超声弹性成像定量分析对PTCD预后的评估价值. 昆明医科大学学报. 2023(02): 150-155 .
5.	梁亚丽，李馨，夏俊杰. 胰腺癌梗阻性黄疸患者经皮穿刺胆管引流术后发生胰腺炎的危险因素分析. 实用癌症杂志. 2023(08): 1321-1324 .
6.	杨立新，刘茜，周晶晶，唐亚丹，傅鹏，戴峰，白淑芬. 不同方法PTCD应用于梗阻性黄疸治疗中的体会. 现代医用影像学. 2023(12): 2229-2231+2235 .
7.	华建军. 超声引导下经皮肝穿刺胆管引流术治疗对阻塞性黄疸病人胆红素水平与肝功能的影响研究. 贵州医药. 2022(02): 226-227 .
8.	黄道琼，沈小叶，刘骏，刘月娥，陈瑜. 回授法在经皮肝穿刺胆管引流术后的应用. 介入放射学杂志. 2022(03): 294-297 .
9.	彭赵宏，张德志，施万印，赵本胜，熊壮，汪名权，宋文，陶龙香，刘斌，张帅，程翔. ~(125)I粒子支架治疗恶性梗阻性黄疸支架通畅时间的影响因素分析. 安徽医科大学学报. 2022(04): 645-649 .
10.	王玮，陈熙，罗丹，李启祥，尹合坤. 不同姑息性引流术对低位恶性梗阻性黄疸的近远期疗效及安全性分析. 当代医学. 2022(19): 39-42 .
11.	买买提·瓦司力，高旭升，司俊杰，徐峰. 经皮肝穿引流和支架植入在恶性梗阻性黄疸患者治疗的疗效评价. 新疆医学. 2022(07): 770-772+809 .
12.	王颖. 彩超引导经皮穿刺肝胆管引流术治疗梗阻性黄疸的临床研究. 中国医疗器械信息. 2022(15): 123-125 .
13.	宋飞，向盈盈，车佳音，李红阳，徐文勇，魏凌潇，黄明. 胆道~(125)I粒子支架与金属裸支架治疗Bismuth Corlette Ⅲ型胆管癌合并梗阻性黄疸的临床对比. 昆明医科大学学报. 2022(11): 85-89 .
14.	冉庆. ERCP联合PTCD胆总管支架置入胆管引流治疗恶性梗阻性黄疸的临床价值. 医学食疗与健康. 2021(04): 86-87 .
15.	王锦程，余佩和，苏松，李波. 经内镜鼻胆管引流术与经内镜胆道支架置入术在低位恶性梗阻性黄疸术前胆道引流效果比较的Meta分析. 临床肝胆病杂志. 2021(04): 863-867 . 本站查看
16.	马博，周军，周京涛，李建刚，王俊. 胆道支架植入治疗恶性梗阻性黄疸术后并发症的发生因素分析. 现代生物医学进展. 2021(07): 1283-1286 .
17.	张建松，侯森，崔虎啸. 超声引导下经皮肝穿刺胆道引流联合胆管复合支架置入术治疗晚期肝外胆管癌的效果. 癌症进展. 2021(09): 931-934 .
18.	张华安，周晓芳，蒋易君，张淏嘉. NRS-2002联合炎症反应标志物预测恶性梗阻性黄疸患者预后的Nomogram模型构建. 山东医药. 2021(16): 35-40 .
19.	石书伟，王劲. 经皮肝穿刺胆道引流联合金属支架植入术对恶性梗阻性黄疸的影响. 黑龙江医学. 2021(15): 1608-1609 .
20.	宋英茜，陶冶. 梗阻性黄疸经皮肝穿刺胆道引流术后胆道感染的病原菌特点及其危险因素分析. 中国实用乡村医生杂志. 2021(02): 33-36 .
21.	张志强，韩涛，崔钢，王奕，蔡恒烈，廖骞. 右肝管入路单通道横跨左右肝管引流治疗汇管区恶性梗阻性黄疸的临床研究. 中国普通外科杂志. 2021(12): 1503-1508 .
22.	傅建英. 内镜介入治疗急性梗阻性黄疸的疗效及对患者炎症因子的影响. 中外医疗. 2021(33): 57-60 .
23.	李蔚，王锡斌，崔卫东，杨青，刘会苗，杨金雨，王锡斌. 超声引导下经皮经肝胆管穿刺引流术治疗急性梗阻性化脓性胆管炎患者疗效分析. 实用肝脏病杂志. 2020(03): 447-450 .
24.	李磊. 胆道支架联合经皮肝穿刺胆管引流术对晚期恶性梗阻性黄疸的临床应用价值. 名医. 2020(08): 85-86 .
25.	张蓓，答秀维，张乐. 经皮肝穿刺胆道外引流治疗恶性梗阻性黄疸疗效及对患者细胞免疫功能、血清直接胆红素、超敏C反应蛋白水平的影响. 陕西医学杂志. 2020(10): 1249-1252 .
26.	朱超，刘会春，胡小四，庞青，陈邦邦，李传涛. 胆道双支架联合~(125)I粒子腔内照射治疗恶性肝门部胆道梗阻的疗效分析. 介入放射学杂志. 2020(11): 1100-1104 .
27.	姜磊，都晓英，孙医学，张大坤，周凯，徐建中，陈芳芳. PTBS术治疗恶性梗阻性黄疸的临床价值及预后因素分析. 蚌埠医学院学报. 2019(09): 1202-1205+1209 .
28.	江新华. 64层螺旋CT3D成像与MRCP成像技术对胆道梗阻性疾病的诊断价值. 江西医药. 2019(11): 1336-1340 .
29.	吴子鑫，吴申伟. 经皮肝穿刺胆道支架植入治疗对恶性梗阻性黄疸患者肝功能指标、炎症指标的影响. 齐齐哈尔医学院学报. 2019(24): 3098-3099 .
30.	武飞. 经皮肝穿刺胆管引流术与Roux-en-Y胆肠吻合术治疗恶性梗阻性黄疸患者的对比研究. 中国药物与临床. 2019(23): 4098-4100 .

Other cited types(4)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1448) PDF downloads(241)

Role of the specific inhibitor of 5-lipoxygenase-activating protein MK886 in inhibiting alcoholic liver disease in mice

DOI: 10.3969/j.issn.1001-5256.2019.08.028